Campuses: FH.com Home button

Clinical Trials Currently Open

Below is a list of clinical trials currently offered at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinators at (386) 231-4023 or (386) 231-4026.

 

Breast Cancer Studies

S1007: Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. 

https://clinicaltrials.gov/ct2/show/study/NCT01272037?show_desc=Y#desc

S1207: “Phase III, Randomized Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

https://clinicaltrials.gov/ct2/show/NCT01674140

Lung Cancer Studies

S0819 Phase III Randomized Study of Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (temp. closed)

https://clinicaltrials.gov/ct2/show/NCT00946712

Melanoma Studies

Castle Bioscience:  Development and Validation of a Gene Expression Assay to Predict the Risk of Metastatic Disease in Malignant Cutaneous Melanoma  

Amgen 20110266: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of  Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB  to IVM1a Melanoma

https://clinicaltrials.gov/ct2/show/NCT02211131?term=Amgen+20110266&rank=1

Amgen 20120166: A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec  for the Treatment of Subjects With Unresected,Stage lllB to IVM1c Melanoma (coming soon)

https://clinicaltrials.gov/ct2/show/NCT02147951

Amgen 20120139:    "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec."  (coming soon)

https://clinicaltrials.gov/ct2/show/NCT02173171

Glioblastoma Studies

A221101 “A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodfinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma  

https://clinicaltrials.gov/ct2/show/study/NCT01781468?show_locs=Y#locn